简介：Objective:Anlotinibhydrochlorideisamultitargettyrosinekinaseinhibitorthattargetsvascularendothelialgrowthfactorreceptor,fibroblastgrowthfactorreceptor,platelet-derivedgrowthfactorreceptor,c-Kit,andc-MET;therefore,itexhibitsbothantitumorandanti-angiogeneticactivities.AphaseIIItrialhasshownthatanlotinibimprovedprogression-freesurvival(PFS)andoverallsurvival(OS)inpatientswithadvancednon-smallcelllungcancer(NSCLC),whopresentedwithprogressivediseaseorintoleranceafterstandardchemotherapy.Thisstudyaimedtoanalyzethecharacteristicsofpatientsreceivinganlotinibtreatmenttodeterminethedominantpopulationswhoarefitforthetreatment.Methods:DatawerecollectedfromMarch2015toJanuary2017fromarandomized,double-blind,placebo-controlled,multicenter,phaseIIItrialofanlotinib(ALTER0303).Atotalof437patientswereenrolledandrandomlyallocated(2:1)totheanlotinibandplacebogroups.Kaplan–Meieranalysisandlog-ranktestwereperformedtocomparePFSandOS.Coxproportionalhazardsmodelwasadoptedformultivariateprognosticanalysis.Results:Multivariateanalysisindicatedthathighpost-therapeuticperipheralbloodgranulocyte/lymphocyteratioandelevatedalkalinephosphataselevelswereindependentriskfactorsforPFS.Meanwhile,elevatedthyroid-stimulatinghormone,bloodglucose,andtriglyceridelevels;hypertension;andhand–footsyndromewereindependentprotectivefactorsofPFS.Highposttherapeuticperipheralbloodgranulocyte/lymphocyteratio,anEasternCooperativeOncologyGroup(ECOG)score≥2,andthesumofthemaximaltargetlesionlengthatbaselinewereindependentriskfactorsofOS,andhypertriglyceridemiawasanindependentprotectivefactorofOS.Conclusions:ThisstudypreliminarilyexploredthepossiblefactorsthataffectedPFSandOSafteranlotinibtreatmentinpatientswithadvancedrefractoryNSCLC,andthebaselinecharacteristicsofthetherapeuticallydominantpopulationswere

简介：